amniotic therapies – Dr. Wade McKenna

You Need Your Knees

Did you ever know just how important your knees are? The knees act like a hinge, and provide steadiness and strength to support the entire body. That’s right, the entire body. Your knees serve as a critical function for standing, walking and running of course, and the fun-filled motions like dancing, jumping, twirling and turning.

When a knee (or knees) give out, it can affect your entire body, even your entire wellbeing. It may affect your ability to perform sports, or even basic functions like standing up from your favorite chair or walking outside to get the mail.

 

Knee replacement surgery is of course an option, and a really good option to get up and running (or walking) again. Dallas-based board certified orthopedic surgeon, Dr. Wade McKenna has performed over 20,000 surgeries, so he is more than qualified to make any repairs to your precious knees. But what if there was a quicker way to heal without a complete knee overhaul?

 

One of the breakthrough technologies that Dr. McKenna specializes in is called Stemnexa. Stemnexa combines a patient’s own bone marrow stem cells with amniotic tissue (donated from a mother after a live birth) to treat bone, muscle, tendon, ligament and cartilage injury in the knee. The amniotic tissue that Dr. McKenna uses in the procedure is composed of collagens and other proteins, which provide solution that supports both tissue growth and new collagen production during tissue regeneration and repair process. Though it sounds technical, the bottom line is that this procedure works, and patients have had amazing results from this relatively not invasive method.

 

Not sure what the next option is? We are here to help. If you are suffering with pain or discomfort, we would love to help ease your aches. If you are interested in either traditional surgery or learning more on how Stemnexa can benefit you, contact us today at info@drwademckenna.com. We are so excited to connect, and get to know you, and your knees better.

 

Knee replacement surgery

Study on Compensated Rotator Cuff Tear Arthropathy by Orthopedic Surgeon and Stem Cell Specialist, Wade McKenna, DO Published in Techniques in Shoulder and Elbow Surgery

Study on Compensated Rotator Cuff Tear Arthropathy by Orthopedic Surgeon and Stem Cell Specialist, Wade McKenna, DO Published in Techniques in Shoulder and Elbow Surgery

Dallas-Fort Worth, Texas (PRWEB) November 08, 2015

A Study by orthopedic surgeon and stem cell specialist, Dr. Wade McKenna of the Riordan-McKenna Institute entitled, “Outpatient Treatment of Compensated Cuff Arthropathy Using Inlay Arthroplasty With Subscapularis Preservation” is published in the December edition of Techniques in Shoulder and Elbow Surgery.

Picture of Wade McKenna, DO

Dr. McKenna is co-founder and chief medical officer of the Riordan-McKenna Institute of Regenerative Orthopedics (RMI) in Southlake, Texas. Co-author of this work is Troy Chandler, PA-C from North Central Texas Orthopedics in Decatur, Texas.

Rotator cuff tear arthropathy sometimes develops in patients who have had a very large, long-standing rotator cuff injury. In CTA, changes in the shoulder due to the rotator cuff tear cause arthritis and lead to destruction of joint cartilage.

The Shoulder HemiCAP® restoration procedure is designed to match the shape and contour of individual patient’s cartilage and joint surface and be an ideal alternative to shoulder replacement. It simply recreates a smooth surface where the cartilage has worn away — similar to a filling for a tooth cavity.

The study examined a consecutive series of 50 CTA patients treated by Dr. McKenna from 2007 to 2015. It concluded that resurfacing the humeral head (shoulder bone) using a HemiCAP shoulder implant preserves the joint and avoids bone loss and complications associated with more invasive procedures like stemmed arthroplasty or total shoulder replacement.

Furthermore, the HemiCAP procedure disrupts the degenerative cycle of early-stage CTA, effectively addresses causes of pain, and avoids further muscle imbalance. The latter is achieved by a special deltoid muscle-splitting approach that leaves the tendon under the shoulder bone intact.

All of these advantages resulted in accelerated recovery and rehabilitation for patients.

“We are very pleased with the positive outcome of this study. Although we specialize in non-surgical stem cell interventions at RMI, sometimes, as in the case of CTA, surgical intervention is indicated. That’s why it’s important for patients to seek out an experienced orthopedic surgeon who, in addition to orthopedic expertise, is well versed on the latest advances in stem cell therapy. A surgeon needs both to know when stem cell therapy may be effective and when surgery, perhaps augmented with biologics like bone marrow aspirate concentrate (BMAC) and AlphaGEMS amniotic tissue product, is a better option,” commented Dr. McKenna.

About Riordan-McKenna Institute (RMI)

RMI specializes in non-surgical treatment of acute and chronic orthopedic conditions using *AlphaGEMS flowable amniotic tissue allograft and bone marrow aspirate concentrate (BMAC) that is harvested using the patented BioMAC bone marrow aspiration cannula. Common conditions treated include meniscal tears, ACL injuries, rotator cuff injuries, runner’s knee, tennis elbow, and joint pain due to degenerative conditions like osteoarthritis. RMI also uses AlphaPATCH amniotic membranes as part of a complete wound care treatment regimen.

RMI also augments orthopedic surgeries with BMAC and AlphaGEMS to promote better post-surgical outcomes.

BMAC contains a patient’s own mesenchymal stem cells (MSC,) hematopoietic stem cells (CD34+), growth factors and other progenitor cells. AlphaGEMS is composed of collagens and other structural proteins, which provide a biologic matrix that supports angiogenesis, tissue growth and new collagen during tissue regeneration and repair.

*AlphaGEMS and AlphaPATCH products are produced by Amniotic Therapies Inc. from donated amniotic tissue after normal healthy births. For more information about AlphaGEMS, please visit: http://www.rmiclinic.com/non-surgical-stem-cell-injections-joint-pain/stemnexa-protocol/

http://www.rmiclinic.com

801 E. Southlake Blvd.

Southlake, Texas

76092

Tel: (817) 776-8155

Toll Free: (877) 899-7836

Fax: (817) 776-8154

For the original version on PRWeb visit: http://www.prweb.com/releases/2015/11/prweb13068117.htm

Dr McKenna Discusses Amniotic Therapies

 

Amniotic Therapies provides superior human amniotic tissue products that naturally enhance the body’s healing ability, providing patients with improved healing.

Amniotic Therapies’ AlphaPeakTM processing system results in amniotic tissue with the highest concentration of factors involved in healing.

With innovative technology and exceptional results for patients, Amniotic Therapies truly is Leading the Future of Medicine.

http://www.youtube.com/embed?listType=playlist&list=UU82AlVvx5OFwPmVdrVZpMLA

Dr McKenna Attends AAOS Annual Meeting with Amniotic Therapies

New Amniotic Tissue Products Promote Growth for Amniotic Therapies 

Amniotic Team

Dallas, TX (April 14, 2015) – Amniotic Therapies (www.amniotictherapies.com), a company specialized in the processing and distribution of human amniotic tissue products for the biologic and regenerative medicine segments of the healthcare market, announced that the introduction of new products at the 2015 American Academy of Orthopaedic Surgeons (AAOS) Annual Meeting has promoted growth for the business.

Amniotic Therapies’ new products included two additions to its AlphaGEMS flowable amniotic tissue line, AlphaGEMS Micro and AlphaGEMS Nano; and a new line of dehydrated amniotic tissue patches and discs for the ocular market, AlphaVISION.

The AAOS meeting is the largest annual orthopaedic meeting in the United States and was attended by over 31,000 orthopaedic surgeons and healthcare professionals.

Amniotic Therapies CEO, Neil Riordan, PhD said, “The AAOS meeting gave us the opportunity to showcase our products to physicians, health care professionals and current and potential distribution partners. Our products contain high levels of bioactive substances and growth factors that are important for healing and tissue regeneration. These factors also modulate inflammation and help reduce the formation of scar tissue. We are excited by the number of partnerships formed during and because of the meeting.”

Amniotic Therapies and its partner company, Biologic Therapies, conducted live presentations on amniotic tissue and regenerative medicine during the meeting. According to Scott Reynolds, VP of Marketing, “The presentations were well attended and were a great way to get members of our target market to witness the benefits of our products first hand.”